Keith Robison has a post on his Omics! Omics! blog about Roche's seemingly unquenchable thirst for acquisition targets. Robison recaps the recent acquisitions of 454 and NimbleGen, as well as the company's currently-in-play bid for Ventana, and ponders how these units could function together as well as what kind of technology might be next on Roche's shopping list.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.